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Abstract
Aims Heart failure (HF) is common in both men and women, yet disease pathophysiology, presentation, and progression
differ between sexes. Studies addressing whether biomarkers predict new onset HF sex-specifically are scarce. This study
therefore aims to test the sex-specificity of 252 protein biomarkers for new-onset HF.
Methods and results A matched case–control design in patients selected from cohorts within the HOMAGE consortium was
used. Cases (new-onset HF, n = 562) and controls (n = 780) were matched for cohort (PREDICTOR, HEALTH-ABC, & PROSPER),
follow-up time (defined as time from entry to incident HF), and age. Incident HF was defined as first hospitalization for HF.
Targeted plasma proteins (n = 252) were measured using Proximity Extension Assay technology from O-link. To look for sex
differences for new onset HF, we adjusted for cohort, age, and baseline clinical parameters. At baseline, women had a
biomarker profile reflecting activated metabolism and immune responses. However, none of the biomarkers had a significant
interaction with sex in predicting new onset HF, but four biomarkers had a trend towards sex-specificity (P< 0.013). E-selectin
and interleukin 1 receptor antagonist were more female-specific, whereas IL17A and CHIT1 tended to be male sex-specific for
incident HF.
Conclusions The majority of biomarkers associated with incident HF did not significantly differ between women and men,
despite clear differences in biomarkers at baseline.
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Introduction
Heart failure (HF) is a major cause of morbidity and mortality
worldwide and the most frequent cause of hospitalization for
patients over 65 years of age.1 Although life-time risk for HF
is substantial and similar in both men and women, its onset
and phenotype are significantly different between sexes.2–4
In general, women usually develop HF at an older age, expe-
rience a lower quality of life, are more symptomatic, but have
a better prognosis and respond better to therapy.3,5 For ex-
ample, it has been suggested that women may gain greater
benefit from spironolactone6 or respond differently to car-
diac resynchronization therapy.7 Women have more often a
non-ischaemic aetiology and HF with preserved ejection frac-
tion (HFpEF), whereas men are more likely to have ischemic
HF and HF with reduced ejection fraction.3,5 Also, in other
cardiovascular diseases (CVD) such as coronary artery disease
(CAD), atrial fibrillation, and stroke, sex differences exist.8,9
The exact mechanisms behind these sex differences are not
completely understood, but it is thought that hormonal sta-
tus and a different profile of comorbidities such as hyperten-
sion, inflammation, and diabetes mellitus (DM) are likely to
play a major role.2,9 Studies investigating sex differences in
biomarkers predicting incident HF are scarce, and although
absolute levels of biomarkers may be different in men and
women, predictive value does not seem to differ.10 Deeper
insight in sex-specific biomarker profiles may help to improve
sex-specific prediction of incident HF and may also help to
understand the underlying pathophysiology of those sex-
differences. In contrast to previous studies investigating
sex-differences in biomarkers associated with HF, we used a
total of 252 biomarkers in this study. The current study re-
ports on (i) sex-specific associations with a broad panel of
biomarkers at baseline, irrespective of HF development, and
(ii) sex-specific biomarker interactions with new-onset HF.
Methods
Study population
The Heart OMics in AGEing consortium (HOMAGE;
NCT02556450) is an EU-funded programme that aims to iden-
tify and validate biomarkers associated with incident HF in or-
der to develop new and personalized preventive strategies.
The HOMAGE consortium collected data from 20 completed
and ongoing European studies enrolling healthy subjects
and patients at high risk of, or with, CVD. We identified co-
horts in whom individuals had been followed-up until first
hospitalization for HF and patients at high risk of CVD, and
these data were merged in a common database.11 We se-
lected individuals who were hospitalized for HF without prior
diagnosis of HF. Cases of incident HF were identified from
two suitable cohorts (PREDICTOR &12 HEALTH-ABC13) and
one clinical trial (PROSPER11,14). We used a case–control
design to identify a control group matched for cohort,
follow-up time (defined as time between incident HF and
entry to the cohort), age, and sex as was performed in a pre-
vious study.15 The study had two independent phases in
which plasma protein assays were performed: a discovery
phase (phase 1a) and a replication phase (phase 1b) with pa-
tient selection as previously described.15 For phase 1a, cases
and controls were randomly selected in a 2:1 proportion. For
phase 1b, cases and controls were randomly selected in a 1:1
proportion. After exclusion of poor-quality samples, the final
match was 562 HF cases and 780 controls (pooled data),
divided over 286 cases and 515 controls in phase 1a and
276 cases and 265 controls in phase 1b. Clinical data include
baseline characteristics, previous medical history, and routine
haematological and biochemical measurements. The study
was conducted in accordance with the Declaration of
Helsinki and approved by each site’s ethics committees. All
participants provided written informed consent.
Plasma protein assays
A total of 252 targeted plasma proteins were assessed in
baseline samples by TATAA Biocenter (Gothenburg,
Sweden) using PEA chemistry and three pre-designed panels
from Olink Proteomics (Uppsala, Sweden). The methods of
the assays have been published.15 Abbreviations, full names
and respective Olink® multiplex panels of the studied
proteins are described in Supporting Information, Table S1.
The samples were randomized before measurement. The
concentrations of proteins were expressed in Olink’s arbitrary
unit (NPX), which is in a Log2 scale.
Statistical analyses
Continuous variables are expressed as means ± standard
deviation. Categorical variables are presented as frequencies
and percentages. Clinical characteristics were compared
between men and women, and between cases and controls,
using independent sample t-tests for continuous variables
and χ2 tests for categorical variables. Outliers in the plasma
protein data were detected by the Tukey’s fences method
were manually checked and removed before analyses.
Association between biomarkers and sex
To assess the relation of each plasma protein with sex, we
adjusted all analyses for cohort (PREDICTOR,12 HEALTH-
ABC,13 or PROSPER11,14), age, and the pre-specified clinical
HOMAGE risk model for HF (smoking, DM, history of CAD,
serum creatinine, body mass index, systolic blood pressure,
use of antihypertensive medication, and heart rate).16 For
each biomarker, the standardized beta-coefficient of sex is
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reported, with a positive value implying higher levels in
women and a negative value implying higher levels in men.
We corrected for multiple testing using the false discovering
rate of 5% (q value < 0.05). All analyses were performed in
the pooled data and replicated both in phase 1a and phase
1b independently.
Biomarker interactions with sex in the association with
new-onset heart failure
Adjusted Cox linear regression models were performed to
examine associations of individual biomarkers with incident
HF. Next, we tested for biomarker*sex interactions in the
adjusted model for incident HF. In the adjusted models,
we adjusted for age, cohort, and the prespecified clinical
HOMAGE risk model for HF. We corrected for multiple test-
ing using the false discovering rate of 5%. All analyses were
performed in the pooled data and replicated both in phase
1a and phase 1b independently. We defined a suggestive in-
teraction as having (i) a significant interaction with sex with
P < 0.05 in the pooled data, (ii) P < 0.1 in phase 1a and 1b,
and (iii) the coefficients were in the same direction in all
phases. All analyses were conducted in R environment
Version 3.5.
Bio-informatical analysis
We performed gene-enrichment in pathway analysis using all
biomarkers that were significantly enriched in male vs. fe-
male analyses at baseline. The overrepresentation analysis
was performed using Gene Ontology (GO) processes, provid-
ing a computational representation of biological processes
and molecular functions enriched by the significant bio-
markers against proteins on the OLINK panels, introducing
an adjustment for the clustering and correlation of proteins
on the panels, further consolidating the results.17,18 Cluster-
ing of a biomarker within a biological function (inflammation,
metabolism, extracellular matrix, and metalloendopeptidase
activity) is based on the main association of the biomarker
using GO-biological processes, UniProt, and GeneCards.
Results
Study population
The clinical characteristics in men and women in both HF
cases and controls are depicted in Table 1. Cases and controls
were matched for age, sex, cohort, and follow-up time as de-
scribed and performed previously (Table S2).15 Mean
follow-up time (time to incident HF) was 5.5 ± 4.3 years.
Women had higher concentrations of both LDL and HDL,
lower creatinine, were more often non- or ex-smokers, and
had a lower prevalence of CAD. In both men and women,
HF cases were more likely to have hypertension, diabetes,
and CAD at baseline. Body mass index and LDL were signifi-
cantly higher in female cases compared with controls, but
not in men. Male cases had a higher creatinine concentration
compared with male controls.
Sex-specific associations of biomarkers
irrespective of new-onset heart failure
A total of 94 biomarkers were significantly different between
sexes after adjusting for cohort, age, smoking, diabetes
mellitus, history of CAD, serum creatinine, body mass index,
systolic blood pressure, use of antihypertensive medication,
and heart rate in the pooled data and replicated in both
phases independently (P value < 0.05; Table S3). More bio-
markers were higher in women (n = 89) compared with
men (n = 5) (Figure 1). Matrix metalloproteinase-3 (MMP-3)
had the strongest association with male sex (effect size
0.37, P < 0.0001, Table S3, Figure 1). Leptin, fatty
acid-binding protein 4, trefoil factor 3, and low-density lipo-
protein receptor were the biomarkers strongly increased in
women (effect size 0.51, 0.48, 0.30, and 0.26, respectively,
all P < 0.0001; Table S3, Figure 1). The male bio profile was
most strongly associated with metalloendopeptidase activity
(GO:0004222), and the female profile was dominated by im-
mune response (GO:0006955) and regulation of metabolic
processes (GO:0019222), irrespective of HF development
(Figure 1).
Biomarker interaction with sex in the association
with incident heart failure
A total of 93 biomarkers were significantly associated with
incident HF in the pooled data, after adjustment for age,
cohort, and the prespecified clinical HOMAGE risk model
for incident HF (q < 0.05; Table S4). None of the biomarkers
showed a significant interaction with sex for incident HF
after adjustment for multiple testing. Four biomarkers
showed a suggestive interaction with sex for incident HF in
the pooled data (pint < 0.05), and consistent hazard ratios
(HR) in the same direction in both phases (Tables 2 & S5).
In SELE and IL1RA, higher values were associated with
incident HF only in women [HR: 1.13; 95% confidence
interval (CI): 1.05–1.40 and HR: 1.30; 95% CI: 1.14–1.48
respectively], whereas higher values of IL17A and CHIT1
are associated with incident HF only in men (HR: 1.19;
95% CI: 1.06–1.32 and HR: 1.14; 95% CI: 1.01–1.30, respec-
tively; Figure 2; Table 2). However, the suggestive
interaction of IL1RA was the only biomarker remaining after
validating in both phases (phases 1a and 1b), indicating no
strong interaction with sex in biomarkers for the develop-
ment of HF in this population (Table S5).
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Discussion
In this study, we investigated sex-specificity of protein
biomarkers both at baseline levels, and in association with
incident HF in a matched case–control design with 562
cases (new-onset HF) and 780 controls selected out of
different international cohorts within the HOMAGE
consortium.11 Our principal findings are as follows: (i)
several circulating protein biomarkers are significantly
different between sexes at baseline, suggesting the pres-
ence of biological differences; (ii) a majority of biomarkers
was strongly associated with incident HF in both sexes;
and (iii) no robust sex-specific association between a bio-
marker and incident HF was observed, although subtle
sex-related differences were found in four biomarkers
(SELE, IL1RA, IL17, and CHIT1). We speculate that the bio-
logical sex-specific differences may overshadow sex-specific
associations of biomarkers related to incident HF
development.
Biological sex differences in protein biomarkers
Sex is known to have a large influence on biomarker levels in
the blood. Differences in biomarkers can reflect both distinct
physiological and pathophysiological pathways in men and
women, which could be associated with incident HF.19 Sex
differences have been detected in proteomic as well as
transcriptomic profiles in healthy populations,20 in which
the differentially expressed proteins and transcripts seem to
underlie the biological differences in circulating biomarkers.21
Sex hormones, accompanied by differences in fat distribution
among men and women, play a major role in the specific pro-
teomic profiles.21,22 Alterations in circulating biomarkers as-
sociated with cardiometabolic risk can already be measured
in asymptomatic women, which showed the influence of
body composition and cardiac morphology on CVD risk.19,23
We also detected differences in bioprofiles between men
and women irrespective of disease and characterized a bio
profile of immuno-metabolic risk in women.
Figure 1 Sex-specific associations of biomarkers irrespective of new-onset HF. Overview of the 94 biomarkers that are significantly different between
sexes. Positive beta-values indicate higher values in women, negative beta-values indicate higher values in men. Clustering of a biomarker within a
biological function is based on the main association of the biomarker using GO-biological processes, UniProt, and GeneCards.




HR (95% CI) P value HR (95% CI) P value pint
SELE 0.96 (0.84–1.09) 0.55 1.22 (1.05–1.40) 0.005 0.004
IL1RA 1.10 (0.98–1.24) 0.11 1.30 (1.14–1.48) <0.001 0.007
IL17A 1.19 (1.06–1.32) 0.002 0.89 (0.77–1.02) 0.091 0.009
CHIT1 1.14 (1.01–1.30) 0.037 0.93 (0.82–1.05) 0.24 0.013
All associations were adjusted for cohort, age, smoking, diabetes mellitus, history of coronary artery disease, serum creatinine, body mass
index, systolic blood pressure, use of antihypertensive medication and heart failure.
CI, confidence interval; HR, hazard ratio.
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Sex-specific biomarkers in heart failure
Male and female HF patients have different biomarker pro-
files, both on transcriptomic and proteomic levels.24,25 Most
literature focuses on sex differences in biomarkers that are
used in HF management, such as N-terminal pro brain
natriuretic peptide and cardiac troponins. For example,
N-terminal pro brain natriuretic peptide levels tend to be
higher in women with HF compared with men.19,23 We did
not find a sex-specific association for any biomarker with inci-
dent HF, in line with a previous study investigating 10
biomarkers.10 It is possible that the biological differences are
of such magnitude that they overshadow sex-specific associa-
tions related to HF development in this population at risk.25,26
Associations between biomarkers and sex with
incident heart failure
We observed a baseline increase in proteins of the immune
response in women. Endothelial inflammation has been asso-
ciated with HF in women, which could explain the increase in
markers for endothelial leukocyte migration (SELE and IL1RA),
both involved in immunoregulatory and inflammatory pro-
cesses. Up-regulation of SELE mediates the interaction and
adhesion of leukocytes—especially neutrophils—and
cytokine-activated endothelium. It controls inflammation in
many diseases including atherosclerosis and HF.27–29
Increased circulating levels of SELE are associated with an
increased risk of developing essential hypertension and
metabolic syndrome in women, which is an important risk
factor for the development of HFpEF, a HF phenotype that
is predominantly present in women.30–32 IL1RA is a member
of the interleukin-1 family and is also involved in immunolog-
ical and inflammatory processes.33 IL1RA inhibits the activity
of interleukin-1 by binding to the IL1-receptor.34 A
meta-analysis of six population-based cohorts showed that
IL-1RA levels are associated with a higher risk of cardiovascu-
lar disease, as it is induced by endothelial activation, oxida-
tive stress, and subclinical inflammation.35 The role of both
SELE and IL1RA in the inflammatory response and their
association with cardiovascular disease might make them
promising HF biomarkers in women, clearly warranting
further investigation.
Two biomarkers had a suggestive interaction with male
sex in the association with incident HF. CHIT1 is mainly pro-
duced and secreted by activated human macrophages and
plays a role in the inflammatory processes of atherosclero-
sis. Activated macrophages in atherosclerotic plaques in-
duce the formation of foam cells, which are a landmark
for the development of atherosclerosis and myocardial
infarction.36,37 Serum levels of CHIT1 are found to be
elevated in patients with ischemic HF, which is especially
common in men, as result of atherosclerosis.3,38 IL17 is a
proinflammatory cytokine produced by activated T-cells
(T-helper 17 cells).39 Binding to the IL17 receptor leads to
induction of chemokines that recruit immune cells such as
monocytes and neutrophils.40
The finding of sex-specific associations of circulating bio-
markers with incident HF could improve our understanding
of sex-specific mechanisms underlying HF development. Most
biomarkers measured in this study were higher in women
compared with men at baseline; however, most of these
biomarkers reflect biological sex-based differences and to a
lesser extent discriminative between HF cases and controls.
The study design and patient population can be an important
determining factor, as the blood was sampled at time of
inclusion, which was around 5 years2–9 before participants
developed HF. Therefore, the blood sampling might be per-
formed in a too early stage in which the biological differences
overshadow biomarkers related to HF development, Still,
these results are in line with a recent study, investigating
sex-specific biomarkers in 22 765 participants (2095 HF cases
and 20 670 controls). This study showed that biomarkers only
have limited value in improving a clinical HF risk prediction
model.10 In line, biological sex-differences are primarily
present in healthy individuals, and less pronounced in HF
patients, suggesting that the biological differences in bio-
markers might become overshadowed due to HF processes
in a later stage.25
Figure 2 Association of biomarkers with incident heart failure: men vs.
women. Hazard ratios with 95% confidence interval of the biomarkers
that had a suggestive interaction with sex in the association with incident
HF. All associations were adjusted for the prespecified clinical HOMAGE
risk model: smoking, DM, history of coronary artery disease (CAD), serum
creatinine, body mass index (BMI), systolic blood pressure (SBP), use of
antihypertensive medication, and heart rate (HR). The interaction P value
(Pint) denotes the sex*biomarker interaction. CHIT1, chitotriosidase 1;
IL1RA, interleukin 1 receptor antagonist; IL17A, interleukin 17A; SELE,
E-selectin.
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Limitations
The combination of this case–control study design and the
used statistical and bioinformatical analyses does not allow
causality assessment. Therefore, we acknowledge the explor-
atory nature of our study and emphasize the descriptive and
hypothesis generating nature of this study. Incident HF was
defined as first HF hospitalization, neglecting the fact that pa-
tients might be diagnosed with HF before their first hospital-
ization. Also, detailed clinical data such as ejection fraction,
symptoms, and electrocardiogram parameters were not avail-
able, which limited the ability to stratify patients based on HF
with preserved or reduced ejection fraction or other clinical
parameters. Finally, three Olink panels with pre-selected pro-
teins were measured (CVD II, CVD III, and inflammation).
These panels are mainly focused on circulating proteins that
are previously found to be associated with cardiovascular
and inflammatory diseases. Other potentional pathways in-
volved in HF development are not included but could have
enriched the analyses.
Conclusions
The majority of biomarkers associated to incident HF were
broadly similar in women and men. Circulating biomarkers
are predominantly higher in women and reflect biological
sex differences. The at-risk population might be in an early
stage in which biological differences overshadow biomarkers
related to HF development.
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